NCT06165510View on ClinicalTrials.gov

Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

October 31, 2026

Conditions
Persistent Atrial FibrillationAtrial Fibrillation, PersistentAtrium; FibrillationAtrial Arrhythmia
Interventions
DEVICE

Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.

2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.

PROCEDURE

Standard Endocardial Catheter Ablation

Standard percutaneous endocardial catheter ablation of atrial fibrillation

Trial Locations (1)

EC1A 4AS

RECRUITING

St Bartholomew's Hospital, London

Sponsors

Collaborators (1)

AtriCure, Inc.
All Listed Sponsors
collaborator

AtriCure, Inc.

INDUSTRY

lead

Barts & The London NHS Trust

OTHER

NCT06165510 - Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation | Biotech Hunter | Biotech Hunter